US 10780097
Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted A61KA61K31/567A61K31/585
Quick answer
US patent 10780097 (Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients) held by Corcept Therapeutics Incorporated expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/567, A61K31/585, A61K45/06, A61P